AIM Vaccine Co. Ltd.

AIM Vaccine Co., Ltd. researches, develops, manufactures, and sells human vaccines in the People's Republic of China and internationally. Its pipeline includes a tetravalent meningococcal conjugate vaccine in Phase IV trials, 13-valent and 23-valent pneumonia vaccines, an iterative serum-free rabies vaccine, and a bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine in Phase III trials. The company also develops vaccines for hand, foot, and mouth disease, haemophilus influenzae type b, tetanus, influenza, and various mRNA-based vaccines. Formerly Beijing AIM Biological Vaccine Technology Group Co., Ltd., it changed its name to AIM Vaccine Co., Ltd. in September 2020. Incorporated in 2011, it is headquartered in Beijing, the People's Republic of China.